NASDAQ: COLL · Specialty & Generic Drug Manufacturers
Collegium Pharmaceutical (COLL) fair value and price range
As of 14 Nov 2026, Faircurve's model values Collegium Pharmaceutical (COLL) at $25.54 a share. The stock last closed at $25.43, which puts the model's fair value 0.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. Collegium Pharmaceutical, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $24.42 to $25.54 (+4.6%). There are fewer shares than before, so each share's claim on the value changed: most of the move.
What the model makes of itThe price of $25.43 is level with it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 25 Feb 2027. Options prices imply a move of about 27% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give COLL?
The calibrated range for COLL over 63 trading days is $18.69 to $35.13. It sits around the last close, and its width comes from the volatility that COLL's own options imply (93% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $4.94 to $56.50. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Collegium Pharmaceutical, Inc. (COLL) is a specialised pharmaceutical firm. It is dedicated to developing and marketing medications for pain management, with a diverse product lineup aimed at various pain conditions.
The model's fair value for Collegium is $25.54 a share, the midpoint of 2,000 simulations, on the run of 14 Nov 2026. The previous run, on 7 Nov 2026, gave $24.42, so the fair value moved +4.6%. In the model's own words, "There are fewer shares than before, so each share's claim on the value changed: most of the move." The calibrated range over 63 trading days is $20.43 to $30.34, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers input completeness, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.
The model compares Collegium with ANI Pharmaceuticals, Inc. (ANIP) and Alkermes plc (ALKS), both of which have a fair value of their own on the site. Six further comparable companies have no verdict on this date: Amphastar Pharmaceuticals, Inc. (AMPH), Pacira BioSciences, Inc. (PCRX), Phibro Animal Health Corporation (PAHC), Supernus, Inc. (SUPN), Lantheus Holdings, Inc. (LNTH) and Amneal Pharmaceuticals, Inc. (AMRX). The facts available give no quality score, overall or by factor, so this note reports none. Faircurve first valued the company on 11 Jul 2026.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does COLL report earnings, and how has the stock reacted?
Collegium Pharmaceutical's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 21.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. COLL's 30 day implied volatility works out to about 26.9% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across COLL's last 8 reports, ignoring direction, was 7.9%.
What the options market has priced for a month's move in COLL
How does COLL compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Collegium Pharmaceutical in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals, Inc. | $29.17 | $29.56 | +1.3% | Low evidence grade |
| PCRX Pacira BioSciences, Inc. | $36.48 | $36.71 | +0.6% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $35.02 | $36.25 | +3.5% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $70.89 | $78.16 | +10.3% | Fairly valued |
| SUPN Supernus, Inc. | $28.83 | $29.86 | +3.6% | Low evidence grade |
| LNTH Lantheus Holdings, Inc. | $101.72 | $100.47 | -1.2% | Data under review |
| AMRX Amneal Pharmaceuticals, Inc. | $21.23 | $19.34 | -8.9% | Low evidence grade |
| ALKS Alkermes plc | $46.53 | $46.51 | 0.0% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Collegium Pharmaceutical at a glance
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions.
- Market value
- $787M
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $846M
- Consensus revenue growth, next fiscal year
- +6.6%
- Analysts with estimates
- 4
- Beta to the US market
- -0.11
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Collegium Pharmaceutical on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for COLL was $24.42. As of 14 Nov 2026 it is $25.54, a change of +4.6%. There are fewer shares than before, so each share's claim on the value changed: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Collegium Pharmaceutical's valuation
Is Collegium Pharmaceutical stock undervalued or overvalued?
Faircurve's model puts COLL's fair value at $25.54 a share against a last close of $25.43, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is COLL's fair value?
$25.54 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $4.94 to $56.50.
What price range does the model give COLL?
$18.69 to $35.13 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Collegium Pharmaceutical report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has COLL moved on past earnings reports?
Across its last 8 reports the median two session move was 7.9%, ignoring direction. The largest was +18.0% around the report of 6 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for COLL is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on COLL
The model holds no idea open on COLL today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on COLL with their outcomes. A free account is enough.